GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for the continued development and ...

AstraZeneca is the latest pharma company enlisting the services of Chinese biotechs, signing a deal worth up to $5.2bn with ...

The label expansion for Moderna’s jab arrives at a juncture in America’s changing vaccine regulatory landscape.

The US Food and Drug Administration (FDA) has approved the label expansion of AbbVie’s Mavyret (glecaprevir/pibrentasvir).

Late-stage pipeline products can generate demand in the MG market and with diagnosed prevalent cases, will drive growth in ...

Debiopharm has entered a co-research agreement with Alkyon Therapeutics to explore the potential of developing targeted RLTs.

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

Enterome has secured $19m in new private funding to progress its EO2463 OncoMimics immunotherapy, targeting iNHL.

BioNTech has agreed to acquire CureVac for approximately $1.25bn, as the former amps up its strategy to offer cancer ...

The future of US immunisation is up in the air as outspoken critics of vaccines populate an integral recommendation committee ...

SpliceBio has closed a Series B financing round, raising $135m for the clinical development of SB-007 for Stargardt disease.

GlobalData estimates that vutrisiran’s entrance into the ATTR-wt market will change the treatment paradigm.